Switch theme
Sign up to access all valuation multiples
Jubilant Pharmova Ltd is an integrated pharmaceutical company. The company operates in the following segments; Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research, Development and Manufacturing Organisation; and Proprietary Novel Drugs. It generates maximum revenue from the Radiopharma segment which specializes in developing, manufacturing, commercializing, and distributing therapeutic agents in the nuclear medicine domain. Geographically, it derives a majority of its revenue from the Americas and Europe and the rest from India and the Rest of the world.
1978
995
LTM Revenue $868M
LTM EBITDA $142M
$2.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Jubilant Pharmova has a last 12-month revenue (LTM) of $868M and a last 12-month EBITDA of $142M.
In the most recent fiscal year, Jubilant Pharmova achieved revenue of $842M and an EBITDA of $186M.
Jubilant Pharmova expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Jubilant Pharmova valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $868M | XXX | $842M | XXX | XXX | XXX |
| Gross Profit | $591M | XXX | $570M | XXX | XXX | XXX |
| Gross Margin | 68% | XXX | 68% | XXX | XXX | XXX |
| EBITDA | $142M | XXX | $186M | XXX | XXX | XXX |
| EBITDA Margin | 16% | XXX | 22% | XXX | XXX | XXX |
| EBIT | $97.9M | XXX | $94.2M | XXX | XXX | XXX |
| EBIT Margin | 11% | XXX | 11% | XXX | XXX | XXX |
| Net Profit | $71.6M | XXX | $98.2M | XXX | XXX | XXX |
| Net Margin | 8% | XXX | 12% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $158M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 1, 2025, Jubilant Pharmova's stock price is INR 1209 (or $14).
Jubilant Pharmova has current market cap of INR 192B (or $2.2B), and EV of INR 206B (or $2.4B).
See Jubilant Pharmova trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.4B | $2.2B | XXX | XXX | XXX | XXX | $0.55 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 1, 2025, Jubilant Pharmova has market cap of $2.2B and EV of $2.4B.
Jubilant Pharmova's trades at 2.9x EV/Revenue multiple, and 14.8x EV/EBITDA.
Equity research analysts estimate Jubilant Pharmova's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Jubilant Pharmova has a P/E ratio of 31.3x.
See valuation multiples for Jubilant Pharmova and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.2B | XXX | $2.2B | XXX | XXX | XXX |
| EV (current) | $2.4B | XXX | $2.4B | XXX | XXX | XXX |
| EV/Revenue | 2.8x | XXX | 2.9x | XXX | XXX | XXX |
| EV/EBITDA | 17.0x | XXX | 14.8x | XXX | XXX | XXX |
| EV/EBIT | 24.7x | XXX | 28.1x | XXX | XXX | XXX |
| EV/Gross Profit | 4.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | 31.3x | XXX | 29.5x | XXX | XXX | XXX |
| EV/FCF | 101.7x | XXX | -1450.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialJubilant Pharmova's last 12 month revenue growth is 11%
Jubilant Pharmova's revenue per employee in the last FY averaged $0.8M, while opex per employee averaged $0.5M for the same period.
Jubilant Pharmova's rule of 40 is 31% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Jubilant Pharmova's rule of X is 43% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Jubilant Pharmova and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Margin | 16% | XXX | 20% | XXX | XXX | XXX |
| EBITDA Growth | 17% | XXX | 6% | XXX | XXX | XXX |
| Rule of 40 | 31% | XXX | 31% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 43% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 57% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cohance Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Piramal Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Jubilant Pharmova acquired XXX companies to date.
Last acquisition by Jubilant Pharmova was XXXXXXXX, XXXXX XXXXX XXXXXX . Jubilant Pharmova acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Jubilant Pharmova founded? | Jubilant Pharmova was founded in 1978. |
| Where is Jubilant Pharmova headquartered? | Jubilant Pharmova is headquartered in India. |
| How many employees does Jubilant Pharmova have? | As of today, Jubilant Pharmova has 995 employees. |
| Is Jubilant Pharmova publicy listed? | Yes, Jubilant Pharmova is a public company listed on BOM. |
| What is the stock symbol of Jubilant Pharmova? | Jubilant Pharmova trades under 530019 ticker. |
| When did Jubilant Pharmova go public? | Jubilant Pharmova went public in 1995. |
| Who are competitors of Jubilant Pharmova? | Similar companies to Jubilant Pharmova include e.g. Biocon, Syngene International, Dishman Carbogen Amics, Cohance Lifesciences. |
| What is the current market cap of Jubilant Pharmova? | Jubilant Pharmova's current market cap is $2.2B |
| What is the current revenue of Jubilant Pharmova? | Jubilant Pharmova's last 12 months revenue is $868M. |
| What is the current revenue growth of Jubilant Pharmova? | Jubilant Pharmova revenue growth (NTM/LTM) is 11%. |
| What is the current EV/Revenue multiple of Jubilant Pharmova? | Current revenue multiple of Jubilant Pharmova is 2.8x. |
| Is Jubilant Pharmova profitable? | Yes, Jubilant Pharmova is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Jubilant Pharmova? | Jubilant Pharmova's last 12 months EBITDA is $142M. |
| What is Jubilant Pharmova's EBITDA margin? | Jubilant Pharmova's last 12 months EBITDA margin is 16%. |
| What is the current EV/EBITDA multiple of Jubilant Pharmova? | Current EBITDA multiple of Jubilant Pharmova is 17.0x. |
| What is the current FCF of Jubilant Pharmova? | Jubilant Pharmova's last 12 months FCF is $23.7M. |
| What is Jubilant Pharmova's FCF margin? | Jubilant Pharmova's last 12 months FCF margin is 3%. |
| What is the current EV/FCF multiple of Jubilant Pharmova? | Current FCF multiple of Jubilant Pharmova is 101.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
